Luminary_banners_1200x628_v2 (2)
OncLive® and the Ruesch Center for the Cure of Gastrointestinal Cancers announce recipients of the 2024 Luminary Awards in GI Cancers
October 09, 2024 10:00 ET | OncLive®
CRANBURY, N.J., Oct. 09, 2024 (GLOBE NEWSWIRE) -- OncLive, the nation’s leading multimedia resource for oncology professionals, and the Ruesch Center for the Cure of Gastrointestinal (GI) Cancers at...
Luminary_banners_1200x628_v2
OncLive® and the Ruesch Center for the Cure of Gastrointestinal Cancers Name Winners of the 2023 Luminary Awards in GI Cancers
October 11, 2023 10:55 ET | OncLive®
CRANBURY, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- OncLive, the nation’s leading multimedia resource for oncology professionals, and The Ruesch Center for the Cure of Gastrointestinal (GI) Cancers,...
OncLive_Logo__color (1).png
OncLive and the Ruesch Center for the Cure of Gastrointestinal Cancers Name Winners of the 2022 Luminary Awards in Gastrointestinal Cancers
November 09, 2022 09:00 ET | OncLive®
CRANBURY, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- OncLive®, the nation’s leading multimedia resource for oncology professionals, and The Ruesch Center for the Cure of Gastrointestinal (GI) Cancers,...
rhL
Rhizen Pharmaceuticals S.A. announces poster presentation of RP4010, a calcium release-activated calcium (CRAC) channel inhibitor in preclinical models of Gastrointestinal (GI) Cancers at the 2019 AACR Annual Meeting
March 26, 2019 07:00 ET | Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, March 26, 2019 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces poster presentation of RP4010, a novel first-in-class CRAC channel inhibitor in preclinical...